Table 3 Liver biopsy findings of checkpoint inhibitor-associated liver injury
Patient no. | Portal inflammation (0–4) | Lobular injury (0–4) | Confluent necrosis (0–6) | Eosinophils (>5 cells/hpf) | Plasmacytosis (>10 cells/hpf) | Overall appearance | Other histological changes |
|---|---|---|---|---|---|---|---|
Pt 1 | 1 | 1 | 0 | Present | Absent | Lobular hepatitis with borderline biliary changes | Bile ductular reaction, cholangiolitis, and duct injury. |
Pt 2 | 3 | 3 | 0 | Absent | Absent | Lobular hepatitis with features of chronic cholangiopathy | Bile duct injury, early ductopenia, and copper-associated protein deposition, consistent with primary biliary cholangitis |
Pt 3 | 1 | 4 | 0 | Absent | Absent | Lobular hepatitis | Micro-abscesses, steatosis (~10%) |
Pt 4 | 1 | 2 | 0 | Absent | Absent | Lobular hepatitis | Extramedullary hematopoiesis leading to the detection of bone marrow involvement. Steatosis (~20%) |
Pt 5 | 1 | 2 | 2 | Present | Present | Lobular hepatitis with confluent necrosis | None |
Pt 6 | 2 | 3 | 0 | Absent | Absent | Lobular hepatitis | Rare lymphohistiocytic aggregates |
Pt 7 | 1 | 3 | 0 | Absent | Absent | Lobular hepatitis | Multiple lymphohistiocytic aggregates |
